Repligen Corporation (RGEN)

Currency in USD
112.21
-2.98(-2.59%)
Real-time Data·
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
112.01118.20
52 wk Range
100.99175.77
Key Statistics
Prev. Close
115.19
Open
115.15
Day's Range
112.01-118.2
52 wk Range
100.99-175.77
Volume
723.57K
Average Volume (3m)
1.07M
1-Year Change
-8.1443%
Book Value / Share
37.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
178.74
Upside
+59.29%
Members' Sentiments
Bearish
Bullish
ProTips
10 analysts have revised their earnings downwards for the upcoming period

Repligen Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

18 Buy
4 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 178.74
(+59.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy160.00+42.67%-New CoverageMay 14, 2026
JPMorgan
Buy165.00+47.12%180.00MaintainMay 06, 2026
Barclays
Buy160.00+42.67%145.00MaintainMay 06, 2026
Jefferies
Hold142.00+26.62%152.00MaintainMay 05, 2026
Canaccord
Hold145.00+29.29%165.00MaintainApr 20, 2026

Repligen Corporation SWOT Analysis


Bioprocessing Pionee
Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth
Financial Resilience
Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025
Market Dominance
Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership
Future Trajectory
Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion
Read full SWOT analysis

Repligen Corporation Earnings Call Summary for Q1/2026

  • Repligen Q1 2026 EPS of $0.48 beat estimates by 26%, revenue of $194M up 15% YoY; stock surged 6.39% pre-market to $125.76
  • Adjusted gross margin expanded 180bps to 55.5%; operating margin improved 160bps to 15.4% driven by operational efficiencies
  • Strong growth in EMEA and Asia Pacific regions; analytics and chromatography franchises drove revenue performance
  • Company raised 2026 guidance: expects Q3 EPS of $0.48, Q4 EPS of $0.61, and full-year revenue of $824.7M
  • Key risks include supply chain disruptions, currency fluctuations, and competitive pressures; new OEM partnership in China announced
Last Updated: 05/11/2026, 09:54 PM
Read Full Transcript

Earnings

Latest Release
May 05, 2026
EPS / Forecast
0.48 / 0.38
Revenue / Forecast
194M / 192.05M
EPS Revisions
Last 90 days

RGEN Income Statement

Compare RGEN to Peers and Sector

Metrics to compare
RGEN
Peers
Sector
Relationship
P/E Ratio
124.2x9.7x−0.5x
PEG Ratio
0.400.010.00
Price/Book
3.0x2.5x2.6x
Price / LTM Sales
8.4x1.6x3.1x
Upside (Analyst Target)
56.1%51.8%53.2%
Fair Value Upside
Unlock36.2%6.2%Unlock

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
36.47M64.66%4.20B
Other Institutional Investors
31.68M35.34%3.65B
Public Companies & Retail Investors
0.000.00%0.00
Total
68.16M100.00%7.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.62%5,993,054690,340
T. Rowe Price Group, Inc.9.30%5,245,982604,285

People Also Watch

913.00
LITE
+0.24%
733.80
PWR
-1.13%
47.65
TECH
-0.68%
180.29
AVAV
-1.08%
103.72
CRWV
-2.05%

FAQ

What Is the Repligen (RGEN) Stock Price Today?

The Repligen stock price today is 112.21 USD.

What Stock Exchange Does Repligen Trade On?

Repligen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Repligen?

The stock symbol for Repligen is "RGEN."

What Is the Repligen Market Cap?

As of today, Repligen market cap is 6.33B USD.

What Is Repligen's Earnings Per Share (TTM)?

The Repligen EPS (TTM) is 0.91.

When Is the Next Repligen Earnings Date?

Repligen will release its next earnings report on Aug 04, 2026.

From a Technical Analysis Perspective, Is RGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Repligen Stock Split?

Repligen has split 0 times.

How Many Employees Does Repligen Have?

Repligen has 2000 employees.

What is the current trading status of Repligen (RGEN)?

As of May 27, 2026, Repligen (RGEN) is trading at a price of 112.21 USD, with a previous close of 115.19 USD. The stock has fluctuated within a day range of 112.01 USD to 118.20 USD, while its 52-week range spans from 100.99 USD to 175.77 USD.

What Is Repligen (RGEN) Price Target According to Analysts?

The average 12-month price target for Repligen is 178.74 USD, with a high estimate of 220 USD and a low estimate of 142 USD. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +59.29% Upside potential.

What Is the RGEN Premarket Price?

RGEN's last pre-market stock price is 115.30 USD. The pre-market share volume is 80.00, and the stock has decreased by 0.11, or 0.10%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.